Advertisement

The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients

  • Tamires Flauzino
  • Daniela Frizon Alfieri
  • Wildea Lice de Carvalho Jennings Pereira
  • Sayonara Rangel Oliveira
  • Ana Paula Kallaur
  • Marcell Alysson Batisti Lozovoy
  • Damacio Ramón Kaimen-Maciel
  • Karen Brajão de Oliveira
  • Andrea Name Colado Simão
  • Edna Maria Vissoci ReicheEmail author
Original Research Paper

Abstract

Objective

The aim of this study was to evaluate the association between rs3761548 FOXP3 (-3279 C > A) variant and multiple sclerosis (MS), disability, disability progression, as well as transforming growth factor (TGF)-β1 and interleukin (IL)-10 plasma levels in MS patients.

Methods and subjects

The study included 170 MS patients and 182 controls. Disability was evaluated using Expanded Disability Status Scale (EDSS) and categorized as mild (EDSS ≤ 3) and moderate/high (EDSS > 3). Disability progression was evaluated using Multiple Sclerosis Severity Score (MSSS). The rs3761548 variant was determined with polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Plasma levels of TGF-β1 and IL-10 were determined using immunofluorimetric assay.

Results

CA and AA genotypes were associated with MS [odds ratio (OR) 2.03, 95% confidence interval (CI) 1.66–3.53, p = 0.012; OR 8.19, 95% CI 3.04–22.07, p < 0.001, respectively). With the dominant model, the CA + AA genotypes were associated with MS (OR 2.57, 95% CI 1.50–4.37, p < 0.001). In the recessive model, the AA genotype was also associated with MS (OR 5.38, 95% CI 2.12–13.64, p < 0.001). After adjustment by age, ethnicity, BMI and smoking, all these results remained significant, as well as female patients carrying the CA + AA genotypes showed higher TGF-β1 than those carrying the CC genotype (OR 1.35, 95% CI 1.001–1.054, p = 0.043). No association was observed between the genotypes and disability, disability progression and IL-10 levels.

Conclusion

These results suggest that the A allele of FOXP3 -3279 C > A variant may exert a role in the T regulatory cell function, which could be one of the factors involved in the susceptibility for MS in females.

Keywords

Multiple sclerosis Disability rs3761548 FOXP3 variant Transforming growth factor β1 T regulatory cell 

Notes

Author contributions

Conception and research design: EMVR and ANCS; manuscript writing and discussion of results: EMVR, ANCS, and TF; data collection: DRK-M, WLCJP, TF, DFA, APK, and SRO, who contributed equally; laboratory analysis: TF, DFA, MABL, and KBO; statistical analysis: ANCS and DFA. All the authors have read and approved the final manuscript.

Funding

The study was supported by grants from Coordination for the Improvement of Higher Level of Education Personnel (CAPES) of Brazilian Ministry of Education; Institutional Program for Scientific Initiation Scholarship (PIBIC) of the National Council for Scientific and Technological Development (CNPq).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The protocol was approved by the Institutional Research Ethics Committees of University of Londrina, Paraná, Brazil (CAAE: 22290913.9.0000.5231) and all the individuals invited were informed in detail about the research and gave written Informed Consent.

References

  1. 1.
    Sospedra M, Martin R. Immunology of multiple sclerosis. Semin Neurol. 2016;36:115–27.  https://doi.org/10.1055/s-0036-1579739.CrossRefGoogle Scholar
  2. 2.
    Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2016;13:26–36.  https://doi.org/10.1038/nrneurol.2016.187.Google Scholar
  3. 3.
    Ribbons KA, McElduff P, Boz C, et al. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PLoS One. 2015;10:1–11.  https://doi.org/10.1371/journal.pone.0122686.CrossRefGoogle Scholar
  4. 4.
    Kallaur AP, Kaimen-Maciel DR, Morimoto HK, et al. Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review). Int J Mol Med. 2011;28:467–79.  https://doi.org/10.3892/ijmm.2011.731.Google Scholar
  5. 5.
    Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T cell and forkhead box protein 3 as modulators of immune homeostasis. Front Immunol. 2017;8:1–24.  https://doi.org/10.3389/fimmu.2017.00605.Google Scholar
  6. 6.
    Ortona E, Pierdominici M, Maselli A, et al. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita. 2011;52:205–12.  https://doi.org/10.4415/ANN_16_02_12.Google Scholar
  7. 7.
    Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+ CD25 T cells. J Clin Investig. 2003;112:1437–43.  https://doi.org/10.1172/JCI200319441.CrossRefGoogle Scholar
  8. 8.
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.  https://doi.org/10.1038/ni904.CrossRefGoogle Scholar
  9. 9.
    Wan YY, Flavell RA. ‘Yin-Yang’ functions of TGF-β and Tregs in immune regulation. Immunol Rev. 2007;220:199–213.  https://doi.org/10.1111/j.1600-065X.2007.00565.x.CrossRefGoogle Scholar
  10. 10.
    Inoue N, Watanabe M, Morita M, et al. Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin Exp Immunol. 2010;162:402–6.  https://doi.org/10.1111/j.1365-2249.2010.04229.x.CrossRefGoogle Scholar
  11. 11.
    Gao L, Li K, Li F, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci. 2010;57:51–6.  https://doi.org/10.1016/j.jdermsci.2009.09.010.CrossRefGoogle Scholar
  12. 12.
    D’Amico F, Skarmoutsou E, Marchini M, et al. Genetic polymorphisms of FOXP3 in Italian patients with systemic sclerosis. Immunol Lett. 2013;152:109–13.  https://doi.org/10.1016/j.imlet.2013.05.006.CrossRefGoogle Scholar
  13. 13.
    Hashemi V, Farrokhi AS, Tanomand A, et al. Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. Immunol Lett. 2018;204:16–22.  https://doi.org/10.1016/j.imlet.2018.10.001.CrossRefGoogle Scholar
  14. 14.
    Jafarzadeh A, Jamali M, Mahdavi R, et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. J Mol Neurosci. 2015;55:891–7.  https://doi.org/10.1007/s12031-014-0443-z.CrossRefGoogle Scholar
  15. 15.
    Eftekharian MM, Sayad A, Omrani MD, et al. Single nucleotide polymorphisms in the FOXP3 gene are associated with increased risk of relapsing-remitting multiple sclerosis. Hum Antibodies. 2016;24:85–90.  https://doi.org/10.3233/HAB-160299.CrossRefGoogle Scholar
  16. 16.
    Shen Z, Chen L, Hao F, et al. Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J Cell Mol Med. 2010;14:226–41.  https://doi.org/10.1111/j.1582-4934.2008.00370.x.CrossRefGoogle Scholar
  17. 17.
    Wawrusiewicz-Kurylonek N, Chorąży M, Posmyk R, et al. The FOXP3 rs3761547 gene polymorphism in multiple sclerosis as a male-specific risk factor. NeuroMol Med. 2018;20:537–43.  https://doi.org/10.1007/s12017-018-8512-z.CrossRefGoogle Scholar
  18. 18.
    Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.  https://doi.org/10.1002/ana.22366.CrossRefGoogle Scholar
  19. 19.
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRefGoogle Scholar
  20. 20.
    Mikulkova Z, Praksova P, Stourac P, et al. Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2011;300:135–41.  https://doi.org/10.1016/j.jns.2010.08.053.CrossRefGoogle Scholar
  21. 21.
    Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology. 2005;64:1144–51.  https://doi.org/10.1212/01.WNL.0000156155.19270.F8.CrossRefGoogle Scholar
  22. 22.
    Koch MW, George S, Wall W, et al. Serum NSE level and disability progression in multiple sclerosis. J Neurol Sci. 2015;350:46–50.  https://doi.org/10.1016/j.jns.2015.02.009.CrossRefGoogle Scholar
  23. 23.
    Brazil. Brazilian Institute of Geography and Statistics (IBGE). Characteristics of the population and households: results of the universe. 2011; https://ww2.ibge.gov.br/english/estatistica/populacao/censo2010/caracteristicas_da_populacao/default_caracteristicas_da_populacao.shtm. Accessed 3 Jul 2018.
  24. 24.
    Banin Hirata BK, Losi Guembarovski R, Vitiello GAF, et al. FOXP3 allelic variants and haplotype structures are associated with aggressive breast cancer subtypes. Dis Mark. 2017;2017:1–8.  https://doi.org/10.1155/2017/6359603.CrossRefGoogle Scholar
  25. 25.
    Huss DJ, Winger RC, Peng H, et al. TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol. 2010;184:5628–36.  https://doi.org/10.4049/jimmunol.1000288.CrossRefGoogle Scholar
  26. 26.
    Huss DJ, Winger RC, Cox GM, et al. TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE. Eur J Immunol. 2011;41:2987–96.  https://doi.org/10.1002/eji.201141666.CrossRefGoogle Scholar
  27. 27.
    Nylander A, Hafler DA. Multiple sclerosis. J Clin Investig. 2012;122:1180–8.  https://doi.org/10.1172/JCI58649.CrossRefGoogle Scholar
  28. 28.
    Monteyne P, Guillaume B, Sindic CJ. B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor-beta mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. J Neuroimmunol. 1998;91:198–203.CrossRefGoogle Scholar
  29. 29.
    Link J, Söderström M, Olsson T, et al. Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann Neurol. 1994;36:379–86.  https://doi.org/10.1002/ana.410360309.CrossRefGoogle Scholar
  30. 30.
    Hassanzadeh G, Hosseini Quchani S, Sahraian MA, et al. Leukocyte Gene expression and plasma concentration in multiple sclerosis: alteration of transforming growth factor-βs, claudin-11, and matrix metalloproteinase-2. Cell Mol Neurobiol. 2016;36:865–72.  https://doi.org/10.1007/s10571-015-0270-y.CrossRefGoogle Scholar
  31. 31.
    Carrieri PB, Provitera V, Bruno R, et al. Possible role of transforming growth factor-beta in relapsing-remitting multiple sclerosis. Neurol Res. 1997;19:599–600.CrossRefGoogle Scholar
  32. 32.
    Carrieri PB, Provitera V, De Rosa T, et al. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis. A correlation with clinical activity. Immunopharmacol Immunotoxicol. 1998;20:373–82.  https://doi.org/10.3109/08923979809034820.CrossRefGoogle Scholar
  33. 33.
    Nicoletti F, Di Marco R, Patti F, et al. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). Clin Exp Immunol. 1998;113:96–9.CrossRefGoogle Scholar
  34. 34.
    Mokhtarian F, Shi Y, Shirazian D, et al. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. J Immunol. 1994;52:6003–10.Google Scholar
  35. 35.
    Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol. 1995;154:2959–68.Google Scholar
  36. 36.
    Wyss-Coray T, Borrow P, Brooker MJ, Mucke L. Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice. J Neuroimmunol. 1997;77:45–50.CrossRefGoogle Scholar
  37. 37.
    Lalive P, Paglinawan R, Biollaz G, et al. TGF-beta-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway. Eur J Immunol. 2005;35:727–37.  https://doi.org/10.1002/eji.200425430.CrossRefGoogle Scholar
  38. 38.
    He Y, Zhang H, Yung A, et al. ALK5-dependent TGF-β signaling is a major determinant of late-stage adult neurogenesis. Nat Neurosci. 2014;17:943–52.  https://doi.org/10.1038/nn.3732.CrossRefGoogle Scholar
  39. 39.
    Fu S, Zhang N, Yopp AC, et al. TGF-beta induces Foxp3+ T-regulatory cells from CD4+ CD25 precursors. Am J Transplant. 2004;4:1614–27.  https://doi.org/10.1111/j.1600-6143.2004.00566.x.CrossRefGoogle Scholar
  40. 40.
    Parsa R, Lund H, Tosevski I, et al. TGFβ regulates persistent neuroinflammation by controlling Th1 polarization and ROS production via monocyte-derived dendritic cells. Glia. 2016;64:1925–37.  https://doi.org/10.1002/glia.23033.CrossRefGoogle Scholar
  41. 41.
    Yang Y, Weiner J, Liu Y, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206:1549–64.  https://doi.org/10.1084/JEM.20082584.CrossRefGoogle Scholar
  42. 42.
    Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-β-induced Foxp3+ T cells and together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells. Nat Immunol. 2008;9:1347–55.  https://doi.org/10.1038/ni.1677.CrossRefGoogle Scholar
  43. 43.
    Lee PW, Severin ME, Lovett-Racke AE. TGF-β regulation of T cells in multiple sclerosis. Eur J Immunol. 2017;47:446–53.  https://doi.org/10.1002/eji.201646716.CrossRefGoogle Scholar
  44. 44.
    Hoogendoorn B, Coleman SL, Guy CA, et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet. 2003;12:2249–54.  https://doi.org/10.1093/hmg/ddg246.CrossRefGoogle Scholar
  45. 45.
    Park H, Lee N, In JW, et al. Association of Foxp3 polymorphism with allograft outcome in kidney transplantation. Ann Lab Med. 2017;37:420–5.  https://doi.org/10.3343/alm.2017.37.5.420.CrossRefGoogle Scholar
  46. 46.
    Qiu X-Y, Jiao Z, Zhang M, et al. Genetic association of FOXP3 gene polymorphisms with allograft rejection in renal transplant patients. Nephrology. 2012;17:423–30.  https://doi.org/10.1111/j.1440-1797.2012.01561.x.CrossRefGoogle Scholar
  47. 47.
    Misra MK, Mishra A, Pandey SK, et al. Association of functional genetic variants of transcription factor Forkhead Box P3 and nuclear factor-κB with end-stage renal disease and renal allograft outcome. Gene. 2016;581:57–65.  https://doi.org/10.1016/j.gene.2016.01.028.CrossRefGoogle Scholar
  48. 48.
    Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+ CD25− T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004;172:5149–53.CrossRefGoogle Scholar
  49. 49.
    Rich S, Seelig M, Lee HM, Lin J. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells. J Immunol. 1995;155:609–18.Google Scholar
  50. 50.
    He Y, Na H, Li Y, et al. FoxP3 rs3761548 polymorphism predicts autoimmune disease susceptibility: a meta-analysis. Hum Immunol. 2013;74:1665–71.  https://doi.org/10.1016/j.humimm.2013.08.270.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Tamires Flauzino
    • 1
  • Daniela Frizon Alfieri
    • 1
  • Wildea Lice de Carvalho Jennings Pereira
    • 1
    • 2
  • Sayonara Rangel Oliveira
    • 3
  • Ana Paula Kallaur
    • 1
  • Marcell Alysson Batisti Lozovoy
    • 1
    • 3
  • Damacio Ramón Kaimen-Maciel
    • 4
  • Karen Brajão de Oliveira
    • 5
  • Andrea Name Colado Simão
    • 1
    • 3
  • Edna Maria Vissoci Reiche
    • 1
    • 3
    Email author
  1. 1.Laboratory of Applied Immunology, Health Sciences CenterUniversity of LondrinaLondrinaBrazil
  2. 2.Outpatient Clinic for Neurology, University HospitalState University of LondrinaLondrinaBrazil
  3. 3.Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University HospitalState University of LondrinaLondrinaBrazil
  4. 4.Hospital Santa Casa de Misericórdia de LondrinaLondrinaBrazil
  5. 5.Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences CenterState University of LondrinaLondrinaBrazil

Personalised recommendations